Navigation Links
New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
Date:6/3/2010

class="xn-person">Andre Goy, M.D., Deputy Director and Chief, Lymphoma at the John Theurer Cancer Center collaborated with researchers at other major cancer centers to examine the value of adding rituximab to FND (fludarabine, mitoxantrone, and dexamethasone) combination therapy for relapsed indolent B-cell lymphoma.  While rituximab is often used as a treatment option for patients with this condition, optimal therapy remains controversial.  In phase I-II studies by this research group, they observed a complete remission rate of 48% using FND for this cancer. Adding rituximab to the treatment regimen, they achieved a five-year overall survival rate of 84% and a nine-year rate of 53%.  

The researchers concluded that rituximab-FND combination therapy is a very active and well tolerated regimen for relapsed indolent B-cell lymphoma. Patients who received this therapy were also able to receive stem cell transplants, and had favorable outcomes.  

Optimal front-line therapies for mantle cell lymphoma.  (Abstract number 8067; poster session, June 5, 8:00 a.m.12:00 p.m.)

Tatyana Feldman, M.D., Attending, Lymphoma, the John Theurer Cancer Center and colleagues conducted a retrospective analysis of cases at the John Theurer Cancer Center in order to compare the survival of newly diagnosed mantle cell lymphoma patients who were given three distinct first-line treatment regimens. The study was conducted because there is no consensus on the best treatment for this subset of patients, and because data from randomized studies are not available. Recent analyses however, strongly support the use of high-dose treatments for these patients. The researchers' analyzed data to compare the overall survival of patients
'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
2. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand
4. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
5. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
6. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
7. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Tumor-Targeted Rexin-G Prolongs Survival in Gemcitabine-Resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
9. Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 A Geisinger researcher on ... for a Centers for Disease Control and Prevention (CDC) ... public health concern. Joseph Boscarino , ... of a team of researchers nominated for the Centers ... Science Award for Data Methods and Study Design. ...
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced ... - Global Strategic Business Report" report to their offering. ... Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The report ... , Europe , Asia-Pacific ... are provided for the period 2012 through 2020. Market data ...
(Date:8/19/2014)... Lenexa, KS (PRWEB) August 19, 2014 ... to offer fast and cost-effective metabolite production from ... and proprietary chemistry platform, the technology enables convenient ... issues. According to XenoTech’s Vice President of ... metabolite synthesis for assessing clinical risk can be ...
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
Breaking Biology Technology:Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... Sept. 1 Express Scripts, Inc. (Nasdaq: ESRX ) announced that ... Thomas Weisel Partners Healthcare Conference 2009 on September 9, 2009 at ... , Morgan Stanley Global Healthcare Conference on September 15, 2009 at ... , These presentations will also be broadcast via the Internet ...
... PHILADELPHIA, Sept. 1 ERT (Nasdaq: ERES ), announced ... Keith Schneck, the Company,s Executive Vice President and CFO, are scheduled to ... on September 9, 2009 in New York City, New York. , ... Company,s corporate website at http://www.ert.com . The webcast may ...
... Sept. 1 Environmental Tectonics Corporation,s (OTC Bulletin Board: ETCC) ... sale of a BARA-MED((R)) XD Monoplace Hyperbaric Chamber to ... Georgia area. , , Hyperbaric Oxygen ... the patient breathes 100% oxygen while fully enclosed in a ...
Cached Biology Technology:Express Scripts to Present at Investor Conferences 2ERT to Present at Baird's 2009 Health Care Conference on September 9, 2009 2Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 2Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 3Environmental Tectonics Corporation's BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 4
(Date:8/20/2014)... 20, 2014 /CNW/ -  Issue Serious ... quickly become life threatening for some children.    ... million Canadians have food allergies and this number may be ... children are estimated to have food allergies.  ... irritations and hives to breathing difficulties and loss of consciousness. ...
(Date:8/20/2014)... State University, the Wellcome Trust Sanger Institute and the ... Mycobacterium pinnipedii from skeletons found in Peru ... is a relative of the TB bacterium that affects ... These researchers assume that seals carried the pathogens from ... lions was unexpected" comments Sebastien Gagneux, from the Swiss ...
(Date:8/20/2014)... image of the Para and Mato Grosso states of ... set in order to deforest the land. Deforestation is ... where the land is thereafter converted to a nonforest ... farms, ranches, or urban use. The herringbone-patterned tan lines ... in the middle of the image are evidence of ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... MARC (Maximizing Access to Research Careers) Program has announced ... Summer Research Opportunity Program (SROP). The FASEB MARC Program ... underrepresented groups for summer research experiences in the laboratories ... mentors for the students. The FASEB MARC SROP provides ...
... researchers should welcome the news from the Lawrence Berkeley ... scientists has discovered a new and possibly more effective ... implications for advanced biofuels and therapeutic drugs, as genetically ... to play a key role in the green chemistry ...
... could make more tomatoes taste like heirlooms, reports an international ... scientist. The finding, which will be reported in the ... significant implications for the U.S. tomato industry, which annually harvests ... and fresh-market sales. "This information about the gene responsible ...
Cached Biology News:Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program 2Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program 3Undergraduate Student Summer Research Award recipients announced for the 2012 FASEB MARC summer research opportunity program 4Programmable DNA scissors found for bacterial immune system 2Programmable DNA scissors found for bacterial immune system 3Discovery may lead to new tomato varieties with vintage flavor and quality 2
... Prior to siRNA library ... must be identified and verified ... The Silencer CellReady siRNA Transfection ... specifically for optimizing transfection conditions ...
... The MX80 Series of positioning ... linear motor, ballscrew, leadscrew, micrometer, and ... construct high performance, cost-effective multi-axis systems. ... cross-roller bearings, encoder resolutions down to ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: